Background:Intravenous regional anaesthesia is a simple, safe and effective technique with good success rate for upper limb surgeries. The duration of postoperative analgesia is an important limitation of this technique. Various adjuvants have been used to overcome this drawback. In this study we evaluate the effect of dexmedetomidine 0.5 μgkg-1 as an adjuvant for lignocaine intravenous regional anaesthesia.Methods:Sixty patients scheduled to undergo upper limb surgery were randomised to receive intravenous regional anaesthesia with lignocaine alone (Group L) or lignocaine with dexmedetomidine 0.5 μgkg-1 (Group LD). The quality of anaesthesia, onset of sensory and motor blocks and duration of postoperative analgesia were noted.Results:The onset of sensory and motor block was significantly rapid in group LD compared to group L (Group LD v/s Group L, sensory block: 2.5min ± 0.5v/s6.34min ± 0.7; motor block: 8.5min ± 1.05v/s14.78min ± 0.6; P < 0.001). The quality of anaesthesia was superior in group LD compared to group L and the duration of postoperative analgesia was also longer in group LD.Conclusion:Dexmedetomidine 0.5 μkg-1 as an adjuvant to lignocaine for IVRA shortens the onset of sensory and motor blocks, improves the quality of anaesthesia and provides longer postoperative analgesia.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.